Watanabe E, Smith D M, Sun J, Smart F W, Delcarpio J B, Roberts T B, Van Meter C H, Claycomb W C
Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans 70112, USA.
Basic Res Cardiol. 1998 Feb;93(1):30-7. doi: 10.1007/s003950050059.
Administration of growth factors is emerging as a new therapeutic approach for the enhancement of collateral vessel formation in the ischemic heart. We have investigated the effects of intramyocardial delivery of FGF-2 in the presence and absence of heparin on angiogenesis in a porcine model of myocardial infarction. Yorkshire pigs were subjected to myocardial infarction by the placement of an embolization coil in the left anterior descending artery (n = 5). Four to five weeks after creation of an infarct, FGF-2 (10 micrograms) alone or in complex with heparin, heparan sulfate, or heparin agarose beads was injected either into the normal myocardium or along the infarct border area. Histologic evaluation of each injection site was performed 4 to 5 weeks post-injection. The effect of FGF-2 on angiogenesis was evaluated by determining the number of capillaries (diameter < 20 microns (and arterioles (> 20 microns with tunica media) in each area observed. The number of capillaries were not affected by the treatment of FGF-2 both in normal myocardium and infarct border area. However, in the normal myocardium, the number of arterioles were increased with the treatment of FGF-2 alone (85 +/- 59%, P < 0.04), FGF-2 plus heparin (281 +/- 193%, P < 0.004) and FGF-2-coated heparin beads (241 +/- 141%, P < 0.01), as compared to control. Delivery of FGF-2 into the infarct border area, also increased the number of arterioles when FGF-2 was given with heparin (736 +/- 154%, P < 0.001) or heparin beads (700 +/- 109%, P < 0.001), as compared to control. FGF-2 administered with heparin was the most effective method of enhancing angiogenesis as compared to FGF-2 alone, FGF-2 plus heparan sulfate, or FGF-2 coated heparin agarose beads.
生长因子的应用正在成为一种新的治疗方法,用于增强缺血心脏中侧支血管的形成。我们研究了在猪心肌梗死模型中,在有或没有肝素的情况下,心肌内递送FGF-2对血管生成的影响。通过在左前降支动脉放置栓塞线圈使约克夏猪发生心肌梗死(n = 5)。在梗死形成后4至5周,将单独的FGF-2(10微克)或与肝素、硫酸乙酰肝素或肝素琼脂糖珠复合的FGF-2注射到正常心肌或梗死边缘区域。在注射后4至5周对每个注射部位进行组织学评估。通过确定每个观察区域中毛细血管(直径<20微米)和小动脉(>20微米且有中膜)的数量来评估FGF-2对血管生成的影响。在正常心肌和梗死边缘区域,FGF-2治疗均未影响毛细血管数量。然而,在正常心肌中,与对照组相比,单独使用FGF-2(85±59%,P<0.04)、FGF-2加肝素(281±193%,P<0.004)和FGF-2包被的肝素珠(241±141%,P<0.01)治疗可增加小动脉数量。与对照组相比,当FGF-2与肝素(736±154%,P<0.001)或肝素珠(700±109%,P<0.001)一起注射到梗死边缘区域时,也会增加小动脉数量。与单独使用FGF-2、FGF-2加硫酸乙酰肝素或FGF-2包被的肝素琼脂糖珠相比,FGF-2与肝素联合给药是增强血管生成的最有效方法。